Xu Y - Search Results

1

Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2).

Zhao WH, Wang BY, Chen LJ, Fu WJ, Xu J, Liu J, Jin SW, Chen YX, Cao XM, Yang Y, Zhang YL, Wang FX, Zhang PY, Lei B, Gu LF, Wang JL, Zhang H, Bai J, Xu Y, Zhu H, Du J, Jiang H, Fan XH, Li JY, Hou J, Chen Z, Zhang WG, Mi JQ, Chen SJ, He AL. Zhao WH, et al. Among authors: xu y, xu j. J Hematol Oncol. 2022 Jul 6;15(1):86. doi: 10.1186/s13045-022-01301-8. J Hematol Oncol. 2022. PMID: 35794616 Free PMC article. Clinical Trial.

2

A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma.

Zhao WH, Liu J, Wang BY, Chen YX, Cao XM, Yang Y, Zhang YL, Wang FX, Zhang PY, Lei B, Gu LF, Wang JL, Yang N, Zhang R, Zhang H, Shen Y, Bai J, Xu Y, Wang XG, Zhang RL, Wei LL, Li ZF, Li ZZ, Geng Y, He Q, Zhuang QC, Fan XH, He AL, Zhang WG. Zhao WH, et al. Among authors: xu y. J Hematol Oncol. 2018 Dec 20;11(1):141. doi: 10.1186/s13045-018-0681-6. J Hematol Oncol. 2018. PMID: 30572922 Free PMC article. Clinical Trial.

3

MLAA-34 knockdown shows enhanced antitumor activity via JAK2/STAT3 signaling pathway in acute monocytic leukemia.

Lei B, Qian L, Zhang Y, Chen Y, Gao M, Shah W, Cao X, Zhang P, Zhao W, Liu J, Wang J, Ma X, Yang Y, Meng X, Cai F, Xu Y, Luo J, Wang B, Zhang Y, He A, Zhang W. Lei B, et al. Among authors: xu y. J Cancer. 2020 Sep 30;11(23):6768-6781. doi: 10.7150/jca.46670. eCollection 2020. J Cancer. 2020. PMID: 33123268 Free PMC article.

4

Bioinformatics Analysis of Differential Innate Immune Signaling in Macrophages by Wild-Type Vaccinia Mature Virus and a Mutant Virus with a Deletion of the A26 Protein.

Li C, Zhou H, Zhang H, Wang S, Xu Y. Li C, et al. Among authors: xu y. J Virol. 2017 Nov 30;91(24):e01160-17. doi: 10.1128/JVI.01160-17. Print 2017 Dec 15. J Virol. 2017. PMID: 29191991 Free PMC article. No abstract available.

5

Protective effects of resveratrol on acute kidney injury in rats with sepsis.

Luo CJ, Luo F, Bu QD, Jiang W, Zhang W, Liu XM, Che L, Luan H, Zhang H, Ma RX, Sun JP, Xu Y. Luo CJ, et al. Among authors: xu y. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2020 Mar;164(1):49-56. doi: 10.5507/bp.2019.006. Epub 2019 Apr 17. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2020. PMID: 30994109 Free article.

6

Madelung's Disease: Analysis of Clinical Characteristics, Fatty Mass Distribution, Comorbidities and Treatment of 54 Patients in China.

Li R, Wang C, Bu Q, Pu W, Zhou B, Che L, Zhang H, Xu Y, Luan H. Li R, et al. Among authors: xu y. Diabetes Metab Syndr Obes. 2022 Aug 6;15:2365-2375. doi: 10.2147/DMSO.S363836. eCollection 2022. Diabetes Metab Syndr Obes. 2022. PMID: 35966829 Free PMC article.

7

Malnutrition screening and acute kidney injury in hospitalised patients: a retrospective study over a 5-year period from China.

Li C, Xu L, Guan C, Zhao L, Luo C, Zhou B, Zhang X, Wang J, Zhao J, Huang J, Li D, Luan H, Man X, Che L, Wang Y, Zhang H, Xu Y. Li C, et al. Among authors: xu l, xu y. Br J Nutr. 2020 Feb 14;123(3):337-346. doi: 10.1017/S000711451900271X. Br J Nutr. 2020. PMID: 31657292

8

Associations between early thiamine administration and clinical outcomes in critically ill patients with acute kidney injury.

Li X, Luan H, Zhang H, Li C, Bu Q, Zhou B, Tang N, Zhou H, Xu Y, Jiang W, Zhao L, Man X, Che L, Wang Y, Luo C, Sun J. Li X, et al. Among authors: xu y. Br J Nutr. 2022 Jul 28;128(2):183-191. doi: 10.1017/S0007114521003111. Epub 2021 Aug 16. Br J Nutr. 2022. PMID: 34392848

9

Case Report: Tissue Origin Identification for Cancer of Unknown Primary: Gene Expression Profiling Approach.

Pu X, Yang S, Xu Y, Chen B, Wang Q, Gong Q, Wu L. Pu X, et al. Among authors: xu y. Front Oncol. 2021 Nov 11;11:702887. doi: 10.3389/fonc.2021.702887. eCollection 2021. Front Oncol. 2021. PMID: 34858803 Free PMC article.

10

Peripheral Blood Biomarkers Associated With Outcome in Non-small Cell Lung Cancer Patients Treated With Nivolumab and Durvalumab Monotherapy.

Jiang M, Peng W, Pu X, Chen B, Li J, Xu F, Liu L, Xu L, Xu Y, Cao J, Wang Q, Li K, Wang J, Wu L. Jiang M, et al. Among authors: xu l, xu f, xu y. Front Oncol. 2020 Jun 30;10:913. doi: 10.3389/fonc.2020.00913. eCollection 2020. Front Oncol. 2020. PMID: 32695663 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

67,304 results

Search Page